ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Nasdaq Portfolio Solutions Channel
  2. How to Invest in Biotech Next Year
Nasdaq Portfolio Solutions Channel
Share

How to Invest in Biotech Next Year

Karrie GordonDec 15, 2021
2021-12-15

It’s been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to offer investors great performance opportunities. The Wall Street Journal reports that investors who focused on COVID-19 stocks, short selling, and mergers within the industry have reaped excellent returns, and all of those are investing trends that are expected to continue to be profitable for 2022.

With the pandemic still affecting countries globally, COVID-19 vaccine stocks have continued to profit this year; Moderna is a prime example that began the year around $100 a share, hit a peak of close to $500 during the summertime, and is now ending the year close to $275 a share. The introduction of Omicron, the latest, highly contagious variant, has seen a renewed push for boosters and should see demand continue into next year for all of the major COVID vaccine producers.

“Anything that’s Covid-related has done well, or at least held up,” says Brad Loncar at Loncar Investments, which created two biotech exchange traded funds.

It was a big year for mergers as well within biotech, and investors have benefited hugely. One of the major mergers was GW Pharmaceuticals PLC being acquired by JASS Pharmaceuticals in May in a deal worth over $7 billion. GW Pharma makes cannabinoid-based prescription medications and was up almost 90% for the year when it was acquired. Dicerna Pharmaceuticals also had a major acquisition that proved profitable for investors.

Looking ahead, this trend is expected to continue next year as major pharmaceutical companies buy into up-and-coming biotech companies, particularly with smaller companies that might have suffered this year. Short sellers also did well this year with some companies reporting disappointing clinical trials.

Leveraged Returns on Biotech

The ProShares Ultra Nasdaq Biotechnology ETF (BIB B+) is a leveraged option for investors looking for exposure to biotechnology, pharmaceuticals, and COVID-19 vaccine makers.

The fund captures twice the daily return of the underlying Nasdaq Biotechnology Index before fees and taxes. The exposure resets daily, and as such, does not provide a simple 2x multiplier on the return of the underlying index.

Accordingly, BIB should be monitored regularly by potential investors.

By utilizing swap agreements with major banking institutions and investing in shares of the companies tracked within the index, such as BioNTech (BNTX), Moderna (MRNA), Jazz Pharmaceuticals (JAZZ), and Dicerna Pharmaceuticals (DRNA), BIB rebalances daily to align with the index.

BIB carries an expense ratio of 0.95%, with a contractual waiver that ends on September 30, 2022.

For more news, information, and strategy, visit the Nasdaq Portfolio Solutions Channel.


Content continues below advertisement

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X